April 8, 2019 – April 8, 2019 – FACIT is pleased to announce recent successes in its mission to help bridge the capital gap often experienced by early-stage entrepreneurs.
April 2, 2019 – April 2, 2019 – Ontario First investor FACIT congratulates portfolio company Fusion Pharmaceuticals, a clinical-stage biotech developing novel targeted alpha radiotherapies
Read More from FACIT Features: Fusion Pharma completes $105M Series B financing
April 1, 2019 – April 1, 2019 – Triphase Accelerator has dosed their first patient in a Phase 1 clinical trial of TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma.
February 25, 2019 – Fusion Pharma announced the first patient dosing with lead candidate in Phase 1 trial for solid tumors.
February 6, 2019 – “For innovation, open science means open for business”, February 6, 2019
January 29, 2019 – “U.S. biotech giant Celgene invests in Ontario-developed blood-cancer drug in potential $1-billion deal”, January 29, 2019
January 29, 2019 – Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia.
January 10, 2019 – FACIT’s Compass Rose Oncology Fund is providing the follow-on investment. DNAstack also previously received capital from FACIT’s early-stage Prospects Oncology Fund, illustrating FACIT’s strategy to ensure promising companies grow roots and scale up in Ontario.
Read More from FACIT Makes Follow-on Investment in AI-based genomics company, DNAstack
November 12, 2018 – KA Imaging, a recent Prospects Fund recipient, is partnering with Grand River Hospital to conduct a pilot study on the use of a high-resolution multi-energy digital x-ray imager for patients with lung nodules.
October 11, 2018 – Both leaders are passionate supporters of the Ontario life science sector, have broad industry experience and decades of work with entrepreneurial ventures.
Read More from FACIT Welcomes Har Grover and Ken Lawless to the Board